July 27, 2016 4:48 AM ET

Biotechnology

Company Overview of Retrotope, Inc.

Company Overview

Retrotope, Inc. focuses on the development of ways of controlling metabolic processes associated with the oxidative stress conditions. It assesses various target products, such as pharmaceutical candidates, functional foods, cosmetics and skin care additives, dietary supplements, pet product functional foods, and other antioxidative applications. The company was incorporated in 2006 and is based in Los Altos Hills, California.

12133 Foothill Lane

Los Altos Hills, CA 94022

United States

Founded in 2006

Phone:

650-917-9256

Key Executives for Retrotope, Inc.

Founder, Chief Executive Officer and Director
Founder, Chairman of the Board and Memberof Scientific Advisory Board
Age: 73
Founder, Chief Scientific Officer and Director
Compensation as of Fiscal Year 2016.

Retrotope, Inc. Key Developments

Retrotope, Inc. Presents at 2016 BIO International Convention, Jun-07-2016 01:45 PM

Retrotope, Inc. Presents at 2016 BIO International Convention, Jun-07-2016 01:45 PM. Venue: Moscone Center, San Francisco, California, United States.

Retrotope Announces Opening of Second Clinical Trial Site

Retrotope announced the opening of second clinical trial site, the Collaborative Neuroscience Network, LLC. ('CNS') in Long Beach, California, for the ongoing 28-day, first-in-human randomized, double-blind, controlled, ascending dose study of orally dosed RT001 to evaluate the safety, tolerability, pharmacokinetics (PK), disease state, and exploratory endpoints in patients with Friedreich's ataxia (FA). The RT001-002 protocol is a two center study planned for 18 patients with FA who are ambulatory (with or without an assistive device). The primary endpoints are to evaluate the safety and tolerability of two dose levels of RT001 when administered orally to patients with FA for 28 consecutive days; to determine the PK profile of RT001 at both dose levels following a single and multiple oral administration; and to determine the dose for future studies. The secondary endpoints are to evaluate the effects of RT001 on disease state endpoints using the Friedreich's Ataxia Rating Scale neurological sub-score and the Timed 25-Foot Walk (T25FW) performance measurement relevant to ataxia. The University of South Florida trial opened in August, 2015 and remains open for enrollment.

Retrotope Announces Open Enrollment for Friedreich's Ataxia Clinical Trial

Retrotope announced the opening of enrollment for a 28-day, first-in-human, randomized, double-blind, controlled, ascending dose study of orally dosed RT001 to evaluate the safety, tolerability, pharmacokinetics (PK), disease state, and exploratory endpoints in patients with Friedreich's ataxia (FA). The RT001 protocol is a two center study planned for 18 patients with FA who are ambulatory (with or without an assistive device). The primary endpoints are to evaluate the safety and tolerability of two dose levels of RT001 when administered orally to patients with FA for 28 consecutive days; to determine the PK profile of RT001 at both dose levels following a single and multiple oral administration; and to determine the dose for future studies. The secondary endpoints are to evaluate the effects of RT001 on disease state endpoints using the Friedreich's Ataxia Rating Scale neurological sub-score and the Timed 25-Foot Walk (T25FW) performance measurement relevant to ataxia.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Retrotope, Inc., please visit www.retrotope.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.